EN DE
Watch CrystalGenomics Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

CrystalGenomics Inc (083790) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of CrystalGenomics Inc stock KRW 837, price KRW 542, upside +54.4%, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7083790006

CI CrystalGenomics Inc logo Thin data Nov 16, 2026

CrystalGenomics Inc

083790 · KQ

Cheap enough by our rule, but weak company and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Low debt 
Even on cautious assumptions the value is 16% above the price (627.54 KRW). 
Fair value 836.72 KRW · Fairly valued 
Quality 43/100 
Mixed vs. peers (4/10) 
Falling price (downtrend) 
Weak Growth (revenue 5y −1.9 %/yr in KRW) 
Loss-making · -64.6% net margin (TTM) 
Negative free cash flow 
Narrow moat 10/100
Thin data 
Estimate
Watch CrystalGenomics Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

8,480 KRW 542.00 KRW Fair Value 836.72 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 542.00 KRW – 8,480 KRW · fair‑value band 627.54 KRW – 1,046 KRW · the 542.00 KRW price screens below the 836.72 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow CrystalGenomics in your weekly email

Every Wednesday you see whether CrystalGenomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea.

Show moreShow less

Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial.

The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial.

In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services.

The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

Stock analysis

CrystalGenomics Inc (083790) currently trades at 542.00 KRW, while our estimate is 836.72 KRW, so the stock looks roughly fairly valued today (gap 35.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 627.54 KRW (bear) to 1,046 KRW (bull), the price of 542.00 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

CrystalGenomics Inc reported revenue of 27.4B KRW in FY2025 versus 42.4B KRW in FY2021, a compound −10.3%/yr. Reported net income was −3.5B KRW in FY2025.

Key figures

Market cap 41.3B KRW (≈ $31.0M) Micro · P/S ratio 1.69 · Dividend yield 3.3% · Net margin −64.6% · Return on equity −4,221% · Return on assets (EBIT) −10.8% (5-year average) · Operating margin −43.3% · Revenue (TTM) 45.0B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).

What moves the price

The share trades about 67% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 54%, 083790 screens cheaper than that median.

Fair Value

Bear 627.54 KRW Fair Value 836.72 KRW Bull 1,046 KRW
Price 542.00 KRW · Upside +54.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 4
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 62
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+277.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Start year 2020 (pandemic). Over 10 years: +16.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
26.2% (2020) → −95.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 083790, get fair value alerts →

Compare CrystalGenomics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside +54.4% · Top 25%
Profitability
Return on assets −1.6% · Bottom 25%
Net margin (12 months) −64.6% · Bottom 25%
Operating margin (12 months) −43.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −0.8% · Bottom 25%
Dividend yield (12 months) 3.3% · Top 25%
Balance sheet
Debt / equity 0.40× · Highest 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 0.39× · Cheapest 25%
P/S (12 months) 0.92× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 11
FUTURE (revenue growth)0 · sector 67
PAST (return on equity)0 · sector 24
HEALTH (low debt)80 · sector 98
DIVIDEND (yield)66 · sector 27

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,300 KRW 47,019 KRW +144% vs 083790
DongKook Pharmaceutical Co 086450 24,400 KRW 28,372 KRW +16% vs 083790
ST Pharm Co 237690 70,200 KRW 61,182 KRW −13% vs 083790
Vivozon Pharmaceutical Co 082800 2,780 KRW 2,179 KRW −22% vs 083790
Oscotec Inc 039200 32,300 KRW 21,262 KRW −34% vs 083790
NatureCell Co 007390 21,450 KRW 11,176 KRW −48% vs 083790
Mezzion Pharma Co 140410 64,800 KRW 31,450 KRW −51% vs 083790
BINEX Co 053030 6,850 KRW 1,844 KRW −73% vs 083790
Caregen Co 214370 26,600 KRW 5,414 KRW −80% vs 083790
SHUKRAPHAR SHUKRAPHAR ₹82.23 ₹9.14 −89% vs 083790

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CrystalGenomics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CrystalGenomics Inc Fair Value". https://www.fairvalue-calculator.com/stock/083790

Frequently asked questions

Is CrystalGenomics Inc (083790) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 836.72 KRW versus a price of 542.00 KRW, about +54% upside (fairly valued).
What is the fair value of 083790?
Our estimate for CrystalGenomics Inc is 836.72 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 542.00 KRW.
What is the quality score of 083790?
CrystalGenomics Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CrystalGenomics Inc (083790)?
Our calculated price target is the estimate of 836.72 KRW (as of Nov 16, 2026). Cautious scenario 627.54 KRW, optimistic scenario 1,046 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CrystalGenomics Inc stock forecast for 2026?
Our estimate puts fair value at 836.72 KRW, about +54% upside versus a price of 542.00 KRW (fairly valued). Cautious scenario 627.54 KRW, optimistic scenario 1,046 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CrystalGenomics Inc (083790)?
CrystalGenomics Inc reported trailing-twelve-month revenue of about 45.0B KRW (latest available figure, as of Nov 16, 2026).
Does CrystalGenomics Inc pay a dividend?
CrystalGenomics Inc currently shows a dividend yield of 3.31% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of CrystalGenomics Inc (083790)?
CrystalGenomics Inc has a dividend yield of 3.3%.
What is the intrinsic value of CrystalGenomics Inc (083790)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CrystalGenomics Inc it is 836.72 KRW per share (as of Nov 16, 2026), against a price of 542.00 KRW.
Is CrystalGenomics Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 083790 trades below its calculated fair value: price 542.00 KRW, fair value 836.72 KRW, a gap of about +54% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 083790?
No. The price is what the market pays today (542.00 KRW); the fair value is what the company's own numbers justify (836.72 KRW). For CrystalGenomics Inc the two are 294.72 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CrystalGenomics Inc worth?
The market values CrystalGenomics Inc at about 41.3B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 542.00 KRW; our models calculate a fair value of 836.72 KRW per share.
What do the bullish and bearish scenarios say about 083790?
Our models span a range for CrystalGenomics Inc: cautious scenario 627.54 KRW, base 836.72 KRW, optimistic 1,046 KRW per share (as of Nov 16, 2026, price 542.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CrystalGenomics Inc (083790)?
Balance-sheet figures for CrystalGenomics Inc (as of Nov 16, 2026): debt of 0.40 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 083790 from its 52-week high?
CrystalGenomics Inc trades at 542.00 KRW, about 67% below its 52-week high of 1,637 KRW and at the low of 542.00 KRW (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of 836.72 KRW is for.
Which stocks are comparable to CrystalGenomics Inc?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CrystalGenomics Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 542.00 KRW, calculated fair value 836.72 KRW (+54%), Quality Score 43/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. CrystalGenomics Inc currently trades 35% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CrystalGenomics Inc (083790)?
The closing price on Nov 18, 2026 was 542.00 KRW. Our estimate is 836.72 KRW, about +54% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CrystalGenomics Inc right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (627.54 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CrystalGenomics Inc

How large is the market capitalisation of CrystalGenomics Inc (083790)?
The market capitalisation of CrystalGenomics Inc is 41.3B KRW (≈ $31.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CrystalGenomics Inc (083790)?
The price-to-sales ratio of CrystalGenomics Inc is 1.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of CrystalGenomics Inc (083790)?
The dividend yield of CrystalGenomics Inc is 3.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CrystalGenomics Inc (083790)?
The net margin of CrystalGenomics Inc is −64.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CrystalGenomics Inc (083790)?
The return on equity (ROE) of CrystalGenomics Inc is −4,221% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CrystalGenomics Inc (083790)?
On an EBIT basis the return on assets of CrystalGenomics Inc is −10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CrystalGenomics Inc (083790)?
The operating margin of CrystalGenomics Inc is −43.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CrystalGenomics Inc (083790)?
Revenue at CrystalGenomics Inc is down 0.8% versus a year earlier (3y avg +85.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CrystalGenomics Inc (083790) generate?
The free cash flow of CrystalGenomics Inc is −25.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CrystalGenomics Inc (083790) carry?
The net debt of CrystalGenomics Inc is 32.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CrystalGenomics Inc in the live analysis

One click puts CrystalGenomics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.